All In Biotech

Drug Trial Radar · NCT01175356

Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma

Last checked: Nov 20, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

99

Actual

Start

Dec 21, 2011

Primary completion

Sep 28, 2016

Study completion Dec 31, 2025

Sponsor

Lead sponsor
Children's Oncology GroupResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI)
First posted
Aug 4, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 1 year, up to 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot clinical trial studies induction therapy followed by iobenguane I 131 and chemotherapy in treating patients with newly diagnosed high-risk neuroblastoma undergoing stem cell transplant, radiation therapy, and maintenance therapy with isotretinoin. Radioisotope therapy, such as iobenguane I 131, releases radiation that kills tumor cells. Drugs used in chemotherapy, such as carboplatin, etoposide phosphate, busulfan, and melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that are destroyed by iobenguane I 131 and chemotherapy. Giving radioisotope therapy, chemotherapy, and peripheral stem cell transplant may kill more tumor cells.

Conditions

  • Ganglioneuroblastoma
  • Localized Resectable Neuroblastoma
  • Localized Unresectable Neuroblastoma
  • Regional Neuroblastoma
  • Stage 4 Neuroblastoma
  • Stage 4S Neuroblastoma

Interventions

  • 3-Dimensional Conformal Radiation TherapyRadiation

    Undergo radiotherapy

  • Autologous Hematopoietic Stem Cell TransplantationProcedure

    Undergo autologous in vitro-treated peripheral blood stem cell transplantation

  • BusulfanDrug

    Given IV

  • CisplatinDrug

    Given IV

  • CyclophosphamideDrug

    Given IV

  • Doxorubicin HydrochlorideDrug

    Given IV

  • Etoposide PhosphateDrug

    Given IV

  • External Beam Radiation TherapyRadiation

    Undergo radiotherapy

  • In Vitro-Treated Peripheral Blood Stem Cell TransplantationProcedure

    Undergo autologous in vitro-treated peripheral blood stem cell transplantation

  • Intensity-Modulated Radiation TherapyRadiation

    Undergo radiotherapy

  • Iobenguane I-131Radiation

    Given IV

  • IsotretinoinDrug

    Given PO

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • MelphalanDrug

    Given IV

  • Pharmacological StudyOther

    Correlative studies

  • Questionnaire AdministrationOther

    Ancillary studies

  • Therapeutic Conventional SurgeryProcedure

    Undergo surgery

  • Topotecan HydrochlorideDrug

    Given IV

  • Vincristine SulfateDrug

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131Time frame: Up to 6 weeks after course 5 of induction
  2. Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel ChemotherapyTime frame: Up to day -6 of conditioning

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • Phoenix Childrens Hospital

    Phoenix, Arizona

  • Children's Hospital Los Angeles

    Los Angeles, California

  • UCSF Medical Center-Parnassus

    San Francisco, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

  • Children's Hospital Colorado

    Aurora, Colorado

  • Connecticut Children's Medical Center

    Hartford, Connecticut

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Children's Healthcare of Atlanta - Arthur M Blank Hospital

    Atlanta, Georgia

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • C S Mott Children's Hospital

    Ann Arbor, Michigan

  • UNC Lineberger Comprehensive Cancer Center

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • UT Southwestern/Simmons Cancer Center-Dallas

    Dallas, Texas

  • Cook Children's Medical Center

    Fort Worth, Texas

  • Primary Children's Hospital

    Salt Lake City, Utah

  • Seattle Children's Hospital

    Seattle, Washington

  • Providence Sacred Heart Medical Center and Children's Hospital

    Spokane, Washington

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin

  • Children's Hospital of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.